Sutro Biopharma

NASDAQ STRO

Data sourced from

and

Download Data

Sutro Biopharma Capital Expenditure To Sales 5 year CAGR for the year ending December 31, 2023: -7.08%

Sutro Biopharma Capital Expenditure To Sales 5 year CAGR is -7.08% for the year ending December 31, 2023, a -156.26% change year over year. The capital expenditure ratio measures the proportion of a company's revenue allocated to capital expenditures. It is calculated by dividing capital expenditures by revenue. This ratio indicates the extent to which a company invests in long-term assets relative to its sales. A higher ratio suggests a higher level of investment in the expansion and improvement of the company's asset base. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Sutro Biopharma Capital Expenditure To Sales for the year ending December 31, 2022 was 11.59%, a -53.18% change year over year.
Sutro Biopharma Capital Expenditure To Sales for the year ending December 31, 2021 was 24.76%, a 48.39% change year over year.
Sutro Biopharma Capital Expenditure To Sales for the year ending December 31, 2020 was 16.69%, a 104.86% change year over year.
Sutro Biopharma Capital Expenditure To Sales for the year ending December 31, 2019 was 8.15%, a 100.99% change year over year.

NASDAQ: STRO

Sutro Biopharma

CEO	Mr. William J. Newell J.D.
IPO Date	Sept. 27, 2018
Location	United States
Headquarters	111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees	300
Sector	Healthcare
Industry	Biotechnology

Description

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Key trends